Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
38 studies found for:    " May 30, 2012":" June 29, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" May 30, 2012":" June 29, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Observational Study of HIV Infection in Participants of Seroconvert During Dapivirine Vaginal Ring Trials
Condition: HIV Infections
Intervention: Drug: No Investigational Product
2 Completed An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients
Condition: Human Immunodeficiency Virus (HIV)
Interventions: Drug: darunavir (PREZISTA);   Drug: etravirine (INTELENCE);   Drug: ritonavir;   Drug: Other antiretroviral medications
3 Completed Phase 3 Safety and Effectiveness Trial of Dapivirine Vaginal Ring for Prevention of HIV-1 in Women
Condition: HIV Infections
Interventions: Drug: Dapivirine;   Drug: Placebo
4 Completed Evaluation of Behavioral Intervention for HIV Positive Prisoners in NC and TX
Condition: HIV Infection
Interventions: Behavioral: Text reminders, counseling, and link coordination;   Behavioral: Standard of care - control arm
5 Active, not recruiting Clinical Trial to Reduce Drinking in Women With HIV
Condition: HIV Infection
Interventions: Drug: Naltrexone;   Drug: Placebo
6 Completed Antiretroviral Adherence Evaluation in HIV Pregnant and Postpartum Women
Conditions: HIV Infection;   Pregnancy
7 Completed Linking Infectious and Narcology Care in Russia
Conditions: HIV Infection;   Drug Use
Intervention: Behavioral: LINC Case Management
8 Completed HIV Disclosure and Medication Adherence, a Pilot Study
Condition: HIV Infection
9 Completed
Has Results
Metabolic Abnormalities in HIV-infected Persons
Conditions: Lipodystrophy;   HIV Infection
Interventions: Drug: Metformin;   Drug: Pioglitazone
10 Active, not recruiting Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1265744 10 mg;   Drug: GSK1265744 30 mg;   Drug: GSK1265744 60 mg;   Drug: Efavirenz 600 mg;   Drug: Rilpivirine 25 mg;   Drug: Placebo;   Drug: Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
11 Completed A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Condition: HIV Infections
Interventions: Drug: Doravirine;   Drug: Efavirenz;   Drug: TRUVADA®
12 Completed Adding Maraviroc to the HAART Regimen of Well Controlled HIV-infected Patients
Condition: HIV Infection
Intervention: Drug: Maraviroc
13 Completed Evaluation of Barriers to Postpartum Care in HIV Infected Women
Conditions: HIV Infection;   Pregnancy
Intervention: Other: questionaires and structured interviews
14 Completed A Study of Ritonavir-Boosted Invirase (Saquinavir) in Treatment-Naïve HIV-1 Infected Patients
Condition: HIV Infections
Interventions: Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTIs);   Drug: ritonavir;   Drug: saquinavir [Invirase]
15 Completed Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics
Condition: HIV Infections
Intervention: Drug: FTC 200 mg/TDF 300 mg fixed-dose combination tablet
16 Completed
Has Results
A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247)
Condition: HIV Infections
Interventions: Drug: Raltegravir;   Drug: TUMS® Ultra Strength;   Drug: MINTOX® Maximum Strength
17 Recruiting Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 28 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
Condition: HIV Infections
Interventions: Drug: Lamivudine/zidovudine;   Drug: Efavirenz;   Drug: Raltegravir
18 Completed MARCH Renal Substudy
Conditions: Proteinuria;   HIV
Interventions: Drug: arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors;   Drug: Arm 2 boosted protease inhibitors and maraviroc;   Drug: Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc
19 Completed
Has Results
Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma
Condition: HIV
Intervention: Drug: Etravirine pharmacokinetics in breast milk and plasma
20 Completed Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
Conditions: HIV;   AIDS;   Substance Abuse;   Inpatient
Interventions: Behavioral: Patient Navigation (PN) Group;   Behavioral: Patient Navigator Plus Contingency Management (PN+CM) Group

   Previous Page Studies Shown (1-20) Next Page (21-38) Show next page of results    Last Page
Indicates status has not been verified in more than two years